Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment
Leslie Mukau, Kadia Wormley, Christian Tomaszewski, Bushra Ahmad, Rais Vohra, Andrew A. Herring

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsVeterinary Pharmacology and Anesthesia · Opioid Use Disorder Treatment · Anesthesia and Sedative Agents
We appreciate the interest expressed by the commentators with regard to our tramadol dependence case report.1 However, we respectfully disagree that not testing the tramadol product the patient obtained from Mexico nor testing the patient herself to confirm the presence of tramadol and exclude the presence of other opioids such as fentanyl is a major limitation of our case report.
We are well aware of the role increasingly being played by toxic adulterants and other pharmacologically active components, and specifically fentanyl, in illicitly manufactured pharmaceuticals in the United States and global street markets.2 ^,^ 3 These toxic adulterants either alone or in combination with other pharmacologically active components have been implicated as possible causes of adverse health outcomes, including death.4 Since 2021, illicit fentanyl has been involved in the vast majority of overdose deaths in the United States.5 Our patient was taking extremely high doses of tramadol and would most likely have overdosed and died had it been laced with fentanyl.
To expedite quick initiation of buprenorphine in the emergency department (ED) for patients with opioid use disorder (OUD), the California bridge model, increasingly adopted by many EDs in California and nationwide, does not encourage unnecessary treatment barriers such as diagnostic urine drug testing.6 At the Behavioral Health Outpatient Clinic, where the patient was originally seen, she had been referred for laboratory testing multiple times but did not go due to the coronavirus disease 2019 pandemic and behavioral changes due to her high-dose tramadol substance use disorder.
The majority of patients currently seen for OUD in most EDs are there due to fentanyl abuse, either deliberate or unintentional, and they do not usually have the symptoms that our patient was exhibiting. Seizures are usually a characteristic of high-dose tramadol use.7 Fentanyl, a synthetic μ-selective opioid agonist, which is typically 50–100 times more potent than morphine, does not cause seizures even at high doses. In fact, fentanyl in combination with certain neuroleptic medications as part of therapeutic neuroleptanalgesia can be used to treat seizures.8 ^,^ 9 As of this writing, our patient remains in treatment and not taking illicit tramadol and is currently free of seizures.
We, therefore, strongly believe our patient’s drug issues were most likely due to the use of high-dose tramadol.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Mukau L Wormley K Tomaszewski Cet al. Buprenorphine for high-dose tramadol dependence: a case report of successful outpatient treatment. Clin Pract Cases Emerg Med. 2022;6(1):71–4.35226854 10.5811/cpcem.2021.12.54602 PMC 8885221 · doi ↗ · pubmed ↗
- 2Singh VM Browne T Montgomery J. The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis. Public Health Rep. 2020;135(1):6–10.31738861 10.1177/0033354919887741 PMC 7119254 · doi ↗ · pubmed ↗
- 3Montero F Bourgois P Friedman J, 2022. Potency-enhancing synthetics in the drug overdose epidemic: xylazine (“Tranq”), fentanyl, methamphetamine, and the displacement of heroin in Philadelphia and Tijuana. J Illicit Econ Dev. 2022;4(2):204–22.37009634 10.31389/jied.122PMC 10065983 · doi ↗ · pubmed ↗
- 4United Nations Office on Drugs and Crime. 2017 Global Synthetic Drugs Assessment. Vienna, Austria: United Nations Office on Drugs and Crime. 2017. Available at: https://www.unodc.org/documents/scientific/Global_Drugs_Assessment_2017.pdf. Accessed October 25, 2023.
- 5National Center for Health Statistics. NCHS Fact Sheet. 2021. Available at: https://www.cdc.gov/nchs/data/factsheets/factsheet_Measuring_our_Nations_Health.pdf. Accessed October 25, 2023.
- 6CA Bridge. Rapid implementation of opioid use disorder treatment in the hospital nationwide. 2022. Available at: https://bridgetotreatment.org/resource/rapid-implementation-of-opioid-use-disorder-treatment-in-the-hospital-nationwide/. Accessed October 25, 2023.
- 7Hassamal S Miotto K Dale Wet al. Tramadol: understanding the risk of serotonin syndrome and seizures. Am J Med. 2018;131(11):1382.e 1–6.10.1016/j.amjmed.2018.04.02529752906 · doi ↗ · pubmed ↗
- 8Hagedorn H Kenny M Gordon A Jet al. Advancing pharmacological treatments for opioid use disorder (A Da PT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract. 2018;13(1):25.30545409 10.1186/s 13722-018-0127-z PMC 6293521 · doi ↗ · pubmed ↗
